EMA Authorised: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (efavirenz;emtricitabine;tenofovir disoproxil succinate) — KRKA, d.d., Novo mesto

View source ↗

Summary

The EMA authorised KRKA’s fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil succinate for HIV infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Efavirenz/Emtricitabine/Tenofovir Disoproxil KRKA (efavirenz; emtricitabine; tenofovir disoproxil succinate)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: KRKA, d.d., Novo mesto. Decision date: 16/01/2025